BRAF and melanoma: The development of drugs to target the hyperactivation of the BRAF-MAPK-ERK signaling pathway has led to substantial advances in patients’ overall survival and progression-free survival for melanoma, and the further addition of MEK inhibitors given in combination has improved response rates and survival compared to monotherapy [66].